|
Patient Acceptance of Health Care
|
F01.100.150.750.500 |
|
|
Hydroxy Acids
|
D006880 |
[Organic compounds containing both the hydroxyl and carboxyl radicals.
] |
|
Hydroxyacetylaminofluorene
|
D006881 |
[A N-hydroxylated derivative of 2-ACETYLAMINOFLUORENE that has demonstrated carcinogenic action.
] |
|
Zygote Intrafallopian Transfer
|
E02.875.800.992 |
|
|
Renal Agents
|
D27.505.954.613 |
|
|
Vesicular Stomatitis
|
C01.925.782.580.830.825 |
|
|
Toxicogenetics
|
H02.884.850 |
|
|
Publications
|
L01.178.682 |
|
|
Dictionaries, Medical as Topic
|
L01.178.682.192.836.842.385 |
|
|
Reference Books, Medical
|
L01.178.682.192.836.842 |
|
|
Dental Prosthesis Design
|
E06.912.145 |
|
|
Th1 Cells
|
A15.145.229.637.555.567.569.200.400.500 |
|
|
Life History Traits
|
G05.045.513 |
|
|
Biological Evolution
|
G05.045 |
|
|
Scavenger Receptors, Class B
|
D12.776.543.750.705.940.625 |
|
|
Nitrosourea Compounds
|
D02.654.692 |
|
|
Hydroxychloroquine
|
D006886 |
[A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
] |
|
Adrenergic alpha-1 Receptor Agonists
|
D27.505.519.625.050.100.100.100 |
|
|
Adrenergic alpha-Agonists
|
D27.505.519.625.050.100.100 |
|
|
Hydroxycholecalciferols
|
D006887 |
[Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3.
] |
